halofuginone has been researched along with Bone Loss, Osteoclastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, Q; Cao, X; Crane, J; Cui, Z; Ding, S; Jin, X; Li, C; Qiu, T; Wan, M; Wang, L; Xie, H; Xie, L; Xie, M; Yu, B; Zhen, G | 1 |
| Deselm, CJ; Teitelbaum, SL; Zou, W | 1 |
2 other study(ies) available for halofuginone and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone.
Topics: Animals; Anterior Cruciate Ligament; Bone and Bones; Bone Remodeling; Bone Resorption; Cartilage, Articular; Disease Models, Animal; Disease Progression; Male; Mice; Mice, Inbred C57BL; Osteoarthritis; Osteoclasts; Piperidines; Quinazolinones; Random Allocation; Rats; Rats, Inbred Lew; Transforming Growth Factor beta | 2016 |
Halofuginone prevents estrogen-deficient osteoporosis in mice.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Bone Resorption; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Evaluation, Preclinical; Estrogens; Interleukin-17; Mice; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; Piperidines; Quinazolinones; RANK Ligand | 2012 |